Avoiding animal testing with vegan antibodies

Spin-off project "Ymolution" launched

26-Nov-2024 - A project started at the University Medical Center Greifswald in November that will lead to the founding of a company in just a few months. A research team from the Interfaculty Institute of Genetics and Functional Genome Research has developed a new method for producing nanoantibodies that ...

Designing large new proteins with AI

New method for designing artificial proteins

25-Nov-2024 - Protein design aims to create customized antibodies for therapies, biosensors for diagnostics, or enzymes for chemical reactions. An international research team has now developed a method for designing large new proteins better than before and producing them with the desired properties in the ...

Impressive results against autoimmune disease

Severe systemic lupus no longer detectable after cancer medication treatment

06-Sep-2024 - The team at Charité – Universitätsmedizin Berlin is astounded by the huge improvement seen in a female patient with severe systemic lupus erythematosus (SLE) after being treated with the cancer medication teclistamab. Not long ago, the 23-year-old was wheelchair-bound due to the autoimmune ...

Autoantibodies Cause Lifelong Risk of Viral Infections

19-Jul-2024 - A new study shows that about two percent of the population develop autoantibodies against type 1 interferons, mostly later in life. This makes individuals more susceptible to viral diseases like COVID-19. The study, conducted by UZH researchers together with a USZ team, is based on an analysis of ...

Novel anti-cancer therapy: Prevention or reversal of cancer resistance

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab

18-Jul-2024 - CatalYm announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund (“Forbion Growth”), Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, ...

New antibody harbours great potential for fighting blood cancer

Already tested antibody also shows promise for ALL

03-Jul-2024 - Kiel cancer researchers from Kiel University and UKSH are testing an antibody clinically proven in autoimmune diseases for the treatment of childhood leukaemia and can demonstrate good efficacy against cancer cells in model trials. Acute lymphoblastic leukaemia (ALL) is the most common cancer in ...

Lab-Made Sugars and Nanobodies from Alpacas Against Cancer: Oren Moscovitz Wins Prestigious Hermann Neuhaus Prize

Two start-ups are already working to bring these findings closer to public fruition

18-Jun-2024 - Dr. Oren Moscovitz has been awarded €25,000 by the Max Planck Society for his promising research toward treatments and non-invasive diagnostics for cancer, which could potentially reduce overall cancer-related deaths. Moscovitz and his team exploit unique sugar patterns found on cancer cells and ...

Tacalyx Extends Seed Round to over €14 M to Advance Development of its Cancer Therapeutics Targeting TACAs

17-Jun-2024 - Tacalyx, a privately held biotech company focused on developing novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announces the extension of its seed financing to over €14 M. This extension round was led by new investor Thuja Capital, and as part of the financing, Evan ...

In case of a black widow bite, what can you do?

New antibodies discovered – with fewer side effects and without animal testing

14-Jun-2024 - Black widows spiders are present worldwide with different species. The European black widow (Latrodectus tredecimguttatus) is found in Europe, for example in the Mediterranean region. It prefers to live in dry areas, i.e. regions with low rainfall, high temperatures and dry soils. The female’s ...

Almost two million euros for biotech start-up

BMBF funds DKFZ spin-off for the development of an antibody therapy against pancreatic cancer

12-Jun-2024 - Panosome GmbH, a biotech company founded in Heidelberg in 2020, specializes in the development of monoclonal antibodies for a wide range of medical purposes. The basis for this is the VAST technology platform jointly developed by Panosome and DKFZ. Panosome now wants to use the VAST technology to ...